The War on Vaping
If anti-vaping policies have been good for tobacco producers, they’ve also been good for major pharmaceutical manufacturers. Nearly $100 billion was invested in the development of such conventional nicotine-reduction treatments as patches, gums, and lozenges, and they constitute a $6 billion-per-year business. As CEI’s Minton demonstrated in meticulous detail, the financial and organizational links between the anti-smoking advocacy community, the pharmaceutical industry, trial lawyers, and the public sector were key to the effort of making vaping as difficult as possible.